29.12
-0.92 (-3.06%)
| Penutupan Terdahulu | 30.04 |
| Buka | 29.75 |
| Jumlah Dagangan | 452,607 |
| Purata Dagangan (3B) | 723,680 |
| Modal Pasaran | 1,813,641,856 |
| Harga / Pendapatan (P/E Ke hadapan) | 204.08 |
| Harga / Jualan (P/S) | 55.30 |
| Harga / Buku (P/B) | 4.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | 26.33% |
| Margin Operasi (TTM) | 70.15% |
| EPS Cair (TTM) | 0.820 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3,661.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.20% |
| Nisbah Semasa (MRQ) | 8.41 |
| Aliran Tunai Operasi (OCF TTM) | 69.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 60.20 M |
| Pulangan Atas Aset (ROA TTM) | 7.81% |
| Pulangan Atas Ekuiti (ROE TTM) | 20.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Stoke Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.17 |
|
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.57% |
| % Dimiliki oleh Institusi | 114.81% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Skorpios Trust | 30 Sep 2025 | 2,256,181 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |